Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia
Bone Marrow Transplantation · 2025-02 · 60 (2) · 135-143
DOI: 10.1038/s41409-024-02465-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bone Marrow Transplantation, online erschienen am 13.11.2024. Verfasst von Mary R Christopher und 2 weiteren Autor:innen. Beteiligte Einrichtung: Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplasm, Residual, Nuclear Proteins, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
NPM1 mutated acute myeloid leukemia (AML) comprises roughly 30% of all AML cases and is mainly classified as favorable or intermediate-risk according to the European Leukemia Net stratification. Some patients, however, either have a poor response to initial intensive chemotherapy or ultimately relapse. NPM1 mutations are common, generally stable at early relapse and AML specific, features which make them ideal targets for measurable residual disease (MRD) monitoring. MRD monitoring via molecular analysis during the course of treatment can inform the role of allogeneic stem cell transplantation (HCT) in first remission in patients with NPM1 mutated AML with high-risk co-occurring mutations, particularly FLT3-ITD, and in favorable risk patients who do not achieve defined molecular milestones. In this review, we evaluate the prognostic role of MRD monitoring in NPM1 mutated AML and its use as a predictive biomarker to refine risk stratification and inform decision making regarding treatment. We explore the impact of pre-HCT MRD positivity on post-HCT outcomes in this AML subset, and how HCT-related factors such as conditioning intensity may influence this risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA. nawasm@uchicagomedicine.org.
- Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
ORCID-Profile: Mary R Christopher
Zitieren
APA
Christopher, M. R., Nawas, M. T., & Reagan, J. L. (2025). Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. Bone Marrow Transplantation, 60(2), 135-143. https://doi.org/10.1038/s41409-024-02465-2
Vancouver
Christopher MR, Nawas MT, Reagan JL. Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. Bone Marrow Transplantation. 2025;60(2):135-143. doi:10.1038/s41409-024-02465-2
BibTeX
@article{Christopher2025,
author = {Christopher, Mary R and Nawas, Mariam T and Reagan, John L},
title = {Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia},
journal = {Bone Marrow Transplantation},
year = {2025},
volume = {60},
number = {2},
pages = {135--143},
doi = {10.1038/s41409-024-02465-2}
}
EUVIMED